vs
ORRSTOWN FINANCIAL SERVICES INC（ORRF）与GeneDx Holdings Corp.（WGS）财务数据对比。点击上方公司名可切换其他公司
GeneDx Holdings Corp.的季度营收约是ORRSTOWN FINANCIAL SERVICES INC的1.9倍（$121.0M vs $64.6M），ORRSTOWN FINANCIAL SERVICES INC净利率更高（33.8% vs -14.6%，领先48.4%），过去两年ORRSTOWN FINANCIAL SERVICES INC的营收复合增速更高（39.3% vs 39.2%）
奥尔斯敦金融服务公司是总部位于美国宾夕法尼亚州的区域性银行控股企业，提供零售及商业银行服务，涵盖存款账户、个人与企业贷款、按揭产品、财富管理等业务，主要服务宾州中部及马里兰州北部的个人客户和中小微企业。
GeneDx是一家基因检测企业，2000年由美国国立卫生研究院（NIH）的两位科学家Sherri Bale和John Compton创立，创立初衷是为当时没有商业化检测方案的罕见病及极罕见病患者和家属提供临床诊断服务。公司最初设立于马里兰州及该州蒙哥马利县扶持的生物技术孵化器技术开发中心。
ORRF vs WGS — 直观对比
营收规模更大
WGS
是对方的1.9倍
$64.6M
净利率更高
ORRF
高出48.4%
-14.6%
两年增速更快
ORRF
近两年复合增速
39.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $64.6M | $121.0M |
| 净利润 | $21.8M | $-17.7M |
| 毛利率 | — | 69.6% |
| 营业利润率 | — | -11.8% |
| 净利率 | 33.8% | -14.6% |
| 营收同比 | — | 26.5% |
| 净利润同比 | 19.1% | -424.9% |
| 每股收益（稀释后） | $1.12 | $-0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ORRFWGS
| Q1 26 | $64.6M | — | ||
| Q4 25 | $64.9M | $121.0M | ||
| Q3 25 | $64.4M | $116.7M | ||
| Q2 25 | $62.4M | $102.7M | ||
| Q1 25 | $60.4M | $87.1M | ||
| Q4 24 | $61.8M | $95.6M | ||
| Q3 24 | $64.1M | $76.9M | ||
| Q2 24 | $33.3M | $70.5M |
净利润ORRFWGS
| Q1 26 | $21.8M | — | ||
| Q4 25 | $21.5M | $-17.7M | ||
| Q3 25 | $21.9M | $-7.6M | ||
| Q2 25 | $19.4M | $10.8M | ||
| Q1 25 | $18.1M | $-6.5M | ||
| Q4 24 | $13.7M | $5.4M | ||
| Q3 24 | $-7.9M | $-8.3M | ||
| Q2 24 | $7.7M | $-29.2M |
毛利率ORRFWGS
| Q1 26 | — | — | ||
| Q4 25 | — | 69.6% | ||
| Q3 25 | — | 72.4% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 67.1% | ||
| Q4 24 | — | 69.2% | ||
| Q3 24 | — | 62.2% | ||
| Q2 24 | — | 60.9% |
营业利润率ORRFWGS
| Q1 26 | — | — | ||
| Q4 25 | 42.3% | -11.8% | ||
| Q3 25 | 43.0% | -2.8% | ||
| Q2 25 | 39.6% | 8.7% | ||
| Q1 25 | 37.7% | -5.2% | ||
| Q4 24 | 27.7% | 9.2% | ||
| Q3 24 | -15.4% | -10.1% | ||
| Q2 24 | 29.5% | -15.0% |
净利率ORRFWGS
| Q1 26 | 33.8% | — | ||
| Q4 25 | 33.1% | -14.6% | ||
| Q3 25 | 34.0% | -6.5% | ||
| Q2 25 | 31.2% | 10.5% | ||
| Q1 25 | 29.9% | -7.5% | ||
| Q4 24 | 22.1% | 5.7% | ||
| Q3 24 | -12.3% | -10.8% | ||
| Q2 24 | 23.3% | -41.4% |
每股收益（稀释后）ORRFWGS
| Q1 26 | $1.12 | — | ||
| Q4 25 | $1.11 | $-0.59 | ||
| Q3 25 | $1.13 | $-0.27 | ||
| Q2 25 | $1.01 | $0.36 | ||
| Q1 25 | $0.93 | $-0.23 | ||
| Q4 24 | $0.35 | $0.25 | ||
| Q3 24 | $-0.41 | $-0.31 | ||
| Q2 24 | $0.73 | $-1.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $161.8M | $171.3M |
| 总债务越低越好 | — | $54.5M |
| 股东权益账面价值 | $603.2M | $308.2M |
| 总资产 | $5.6B | $523.7M |
| 负债/权益比越低杠杆越低 | — | 0.18× |
8季度趋势，按日历期对齐
现金及短期投资ORRFWGS
| Q1 26 | $161.8M | — | ||
| Q4 25 | — | $171.3M | ||
| Q3 25 | — | $155.1M | ||
| Q2 25 | — | $134.6M | ||
| Q1 25 | — | $159.2M | ||
| Q4 24 | — | $141.2M | ||
| Q3 24 | — | $116.5M | ||
| Q2 24 | — | $106.9M |
总债务ORRFWGS
| Q1 26 | — | — | ||
| Q4 25 | — | $54.5M | ||
| Q3 25 | — | $54.8M | ||
| Q2 25 | — | $55.1M | ||
| Q1 25 | — | $55.5M | ||
| Q4 24 | — | $55.8M | ||
| Q3 24 | — | $56.1M | ||
| Q2 24 | — | $56.3M |
股东权益ORRFWGS
| Q1 26 | $603.2M | — | ||
| Q4 25 | $591.5M | $308.2M | ||
| Q3 25 | $571.9M | $292.3M | ||
| Q2 25 | $548.4M | $277.1M | ||
| Q1 25 | $532.9M | $257.4M | ||
| Q4 24 | $516.7M | $245.2M | ||
| Q3 24 | $516.2M | $204.5M | ||
| Q2 24 | $278.4M | $194.0M |
总资产ORRFWGS
| Q1 26 | $5.6B | — | ||
| Q4 25 | $5.5B | $523.7M | ||
| Q3 25 | $5.5B | $493.9M | ||
| Q2 25 | $5.4B | $463.9M | ||
| Q1 25 | $5.4B | $446.4M | ||
| Q4 24 | $5.4B | $419.4M | ||
| Q3 24 | $5.5B | $408.8M | ||
| Q2 24 | $3.2B | $389.1M |
负债/权益比ORRFWGS
| Q1 26 | — | — | ||
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.20× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | — | 0.23× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-3.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-7.4M |
| 自由现金流率自由现金流/营收 | — | -6.1% |
| 资本支出强度资本支出/营收 | — | 3.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $14.3M |
8季度趋势，按日历期对齐
经营现金流ORRFWGS
| Q1 26 | — | — | ||
| Q4 25 | $74.7M | $-3.1M | ||
| Q3 25 | $22.8M | $15.8M | ||
| Q2 25 | $24.5M | $10.4M | ||
| Q1 25 | $11.0M | $10.2M | ||
| Q4 24 | $35.0M | $-3.2M | ||
| Q3 24 | $7.5M | $-4.4M | ||
| Q2 24 | $6.4M | $-4.5M |
自由现金流ORRFWGS
| Q1 26 | — | — | ||
| Q4 25 | $70.5M | $-7.4M | ||
| Q3 25 | $22.3M | $9.6M | ||
| Q2 25 | $23.7M | $8.1M | ||
| Q1 25 | $8.6M | $4.1M | ||
| Q4 24 | $33.4M | $-6.2M | ||
| Q3 24 | $7.1M | $-5.0M | ||
| Q2 24 | $6.4M | $-5.9M |
自由现金流率ORRFWGS
| Q1 26 | — | — | ||
| Q4 25 | 108.6% | -6.1% | ||
| Q3 25 | 34.7% | 8.2% | ||
| Q2 25 | 37.9% | 7.8% | ||
| Q1 25 | 14.3% | 4.7% | ||
| Q4 24 | 54.0% | -6.5% | ||
| Q3 24 | 11.1% | -6.6% | ||
| Q2 24 | 19.2% | -8.3% |
资本支出强度ORRFWGS
| Q1 26 | — | — | ||
| Q4 25 | 6.5% | 3.6% | ||
| Q3 25 | 0.8% | 5.3% | ||
| Q2 25 | 1.3% | 2.3% | ||
| Q1 25 | 3.8% | 7.0% | ||
| Q4 24 | 2.6% | 3.2% | ||
| Q3 24 | 0.6% | 0.8% | ||
| Q2 24 | 0.1% | 1.9% |
现金转化率ORRFWGS
| Q1 26 | — | — | ||
| Q4 25 | 3.48× | — | ||
| Q3 25 | 1.04× | — | ||
| Q2 25 | 1.26× | 0.96× | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 2.55× | -0.59× | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.83× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ORRF
| Net Interest Income | $49.0M | 76% |
| Noninterest Income | $15.6M | 24% |
WGS
| Diagnostic Test Third Party Insurance | $101.1M | 84% |
| Diagnostic Test Institutional Customers | $15.5M | 13% |
| Other | $3.4M | 3% |
